FindTrial
Sign In

The effect of drug oral Ibandronate sodium 150mg in patients with bone disease with missing teeth requiring dental implants.

An Evaluation of "The effect of Ibandronate sodium 150mg on alveolar resorption around Dental implants in maxilla and mandible,to compare alveolar changes in osteoporotic and non-osteoporotic patients requiring dental implants.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011420
Enrollment
90
Registered
2018-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 1.Implants in Normal health individuals 2.Implants in proved osteoporotic on calcium and vitamin supplements only.3.Implants in osteoporotic cases with supplement of Ibandronate sodium 150 mg

Interventions

Intervention1: Group-I: Implants in Normal healthY individual-30 Intervention2: GROUP-II: group:II implants in diagnosed osteoporotic patients on calcium and vitamin supplements only-30 Intervention3

Sponsors

Vishnu Dental College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a.History of extraction /tooth loss more than 3 months. b.Normal healthy patients above 40 years indicated for extraction with subsequent dental implants. c.Patients with osteoporosis indicated for oral rehabilitation with dental implants. d.Patients who are advised for full mouth extraction planned for implant prosthesis. e.Partially, completely edentulous patients reporting for the requirement of implant prosthesis. f.Osteoporosis patients under calcium and vitamin-D supplementation other than bisphosphonates

Exclusion criteria

Exclusion criteria: a.Patients on long term corticosteroid therapy. b.Patients with history of liver disease. c.Patients with history of diabetes mellitus. d.Patients with other debilitated disease. e.Patientâ??s with autoimmune diseases

Design outcomes

Primary

MeasureTime frame
1)confidence interval-95% 2)power of study-80% which means that maximum acceptable Type I errors and TypeII errors are 5 and 20 respectively. A)Positive results may be achieved with this study by the oral use of the drug Ibandronate sodium 150mg that can minimize the alveolar resorption around dental implants which might enhance early oral rehabilitation and improve ridge remodeling in implant surgery.Timepoint: within 3 years of time period—

Secondary

MeasureTime frame
A)establish early osseointegration,early rehabilitation in osteoporotic patients by using the drug Ibandronate sodium orally to hinder resorption. achieve sustenance of good bone around dental implants and to design a protocol for the management of alveolar resorption in osteoporotic cases requiring Dental implants.Timepoint: with in 3 years of time period—

Countries

India

Contacts

Public ContactVENKATA RAMANA MURTHY V

Vishnu Dental College

sureshsajjanmc@vdc.edu.in9949433567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026